Functional dyspepsia is a disease, in which there is no organic lesion but chronic and repetitive postprandial fullness, early satiation, epigastric pain, and epigastric burning. Functional dyspepsia is not life-threatening but its symptoms are relapsing and remitting and persist over a lifetime, limiting the social life and reducing the quality of life. Therefore, the treatment for acute relapsing period may help improve the short-term symptoms. Continuous medication may be needed to improve the long-term symptoms. Research designs to demonstrate the short-term efficacy of therapeutic agents may differ from clinical trials to demonstrate long-term efficacy. There are many difficulties in clinical trial design, implementation, and screening because there are no international standards of clinical trials for functional dyspepsia. The purpose of this guideline recommendation is to develop a standard for clinical trials, such as clinical trial subjects and evaluation methods, in the development of therapeutic agents for functional dyspepsia. The ultimate aim is to enhance the safety and efficacy of therapeutic agents for functional dyspepsia and promote the development of new therapeutic agents. 
PRO를 어떻게 개발하고 개발 단계를 기록하는지에 대한 안내는 Table 3에 요약하였다. Table 3 . Developing PROs for FGIDs 1. For FGID registration trials, the FDA and EMA require fit-for-purpose PROs that are specifically designed for the precise target population being studied.
2. As FGIDs are an international phenomenon, it is important to create PROs that can be accurately translated into different languages.
3. All items in a PRO should be carefully tested in cognitive interviews with FGID patients who are representative of the target population.
4. For clinical trials, it is generally recommended to use endpoints with a 1 day recall or less. Table 4 . Defining MCID and Responder Status 1. The main result of the study must be based on the evaluation of the primary outcome measure, as stated in the protocol before the study begins. The primary outcome should be stated in absolute numbers and should include a 95% CI.
2. When trial results are expressed in terms of the proportion of responders in each are of the study, a responder should be defined as someone showing an improvement equal to or greater than the MCID.
3. When continuous measures are used to assess trial results, the differences between treatment arms should be compared with the MCID.
4. When reporting p-values, actual values and not thresholds should be provided. Investigators are encouraged to report the NNT in clinical trials, and the NNH can be calculated based on the risk of adverse effects and can be weighed against the NNT.
5. The primary analysis should be an ITT analysis and must include all patients randomized.
MCID, minimal clinically important difference; CI, confidence interval; NNT, number needed to treat; NNH, number needed to harm; ITT, intention-to-treat. 
